AAV-hAADC gene therapy

Drug Profile

AAV-hAADC gene therapy

Alternative Names: AAV-AADC; AAV-AADC gene therapy; AAV-AADC gene therapy - Voyager Therapeutics; AAV-hAADC-2; AAV2-hAADC; Adeno-associated virus encoding human aromatic L-amino acid decarboxylase (AAV-hAADC-2) - Sanofi Genzyme; AV201; GZ 404477; Parkinson's disease gene therapy-AADC - Sanofi Genzyme; Parkinson's disease gene therapy-AADC - Voyager Therapeutics; VY AADC01

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator University of California at San Francisco
  • Developer National Institutes of Health (USA); Sanofi Genzyme; University of California at San Francisco; Voyager Therapeutics
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Dopamine release stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 20 Jan 2017 Pharmacodynamics data from a phase Ib trial in Parkinson's disease released by Voyager Therapeutics
  • 08 Dec 2016 Interim efficacy, adverse event and pharmacodynamic data from a phase Ib trial in Parkinsons Disease released by Voyager Therapeutics
  • 10 Nov 2016 Voyager Therapeutics plans a placebo-controlled trial for Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top